We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ustekinumab

News List

Cipla takes deal route with Alvotech to enter Australian autoimmune biosimilars market: GlobalData expresspharma
March 22, 2021
Australia continues to focus on reducing healthcare expenditure and encouraging the use of biosimilars over their reference product.
EC approves expanded use of ustekinumab for ulcerative colitis europeanpharmaceuticalreview
September 09, 2019
The biologic treatment ustekinumab has been granted an expanded use for ulcerative colitis within the EU.
Ustekinumab could be approved to treat ulcerative colitis europeanpharmaceuticalreview
January 09, 2019
Ustekinumab has been submitted to be the first interleukin (IL)-12/23 inhibitor licensed for the treatment of ulcerative colitis…
Janssen files Stelara in Europe for ulcerative colitis pharmatimes
January 08, 2019
Janssen has submitted a Group Type II Variation Application to the European Medicines Agency (EMA) seeking approval of Stelara (ustekinumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC).
Stelara induces remission in ulcerative colitis patients pharmatimes
October 11, 2018
Janssen has presented new data showing that a single dose of its biologic Stelara induced clinical remission and response in patients with moderate to severe ulcerative colitis.